Skip to content
Investors Dashboard
Contact
TwitterFacebookInstagramLinkedinYouTube
  • English
  • Spanish
TwitterFacebookInstagramLinkedinYouTube
  • English
  • Spanish
Pharmamar S.A
Pharmamar S.A.
Pharmamar S.APharmamar S.A
  • About PharmaMar
    • Senior Management
    • Management Team Oncology Unit
    • Management Team Virology Unit
    • Board of directors
    • Other Business
    • PharmaMar in the World
    • Corporate Responsibility
    • Our History
  • Patients
    • Therapeutic Indications
    • Collaboration with Patient Associations
    • Clinical trial
  • Products
    • YONDELIS®
    • Lurbinectedin
  • Science & Innovation
    • R&D and Innovation
    • Virology Unit
      • Our Vision
      • Molecular Pharmacodynamics
      • COVID-19, Clinical Development
      • COVID-19, Translational Strategy
    • Oncology Pipeline
    • Cofinanced Projects
    • Collaboration with Scientific Associations
    • Publications
    • Mechanisms of Action
    • Medical meeting presentations
  • Shareholders and Investors
    • Financial Information
      • Annual Reports
      • Interim financial information
      • Financial Statements (Zeltia)
      • Average Period of Payment to Suppliers
    • Notifications sent to CNMV
    • Share Information
      • Share Performance
      • Shares Outstanding
      • Dividends
      • Significant Shareholding & Company Owned-Stock
      • Analysts
    • Debt Obligations
    • Presentations
    • General Shareholders Meetings
    • Corporate Governance
      • Corporate Bylaws
      • General Shareholders’ Meeting Regulations
      • Shareholder Agreements
      • Board of Directors
      • Board of Directors Regulation
      • Annual Report on Corporate Governance
      • Annual Director Remuneration Report
      • Board Committees
      • Internal Regulation Governing Conduct
    • Contact
    • Merger PharmaMar-Zeltia
    • Política de Comunicación con Accionistas
  • Newsroom
    • Press Releases
    • Events calendar
    • Multimedia
      • Videos
      • Infographics
    • Medical meeting presentations
  • Careers
    • Benefits
    • Send us your CV
    • About PharmaMar
      • Senior Management
      • Management Team Oncology Unit
      • Management Team Virology Unit
      • Board of directors
      • Other Business
      • PharmaMar in the World
      • Corporate Responsibility
      • Our History
    • Patients
      • Therapeutic Indications
      • Collaboration with Patient Associations
      • Clinical trial
    • Products
      • YONDELIS®
      • Lurbinectedin
    • Science & Innovation
      • R&D and Innovation
      • Virology Unit
        • Our Vision
        • Molecular Pharmacodynamics
        • COVID-19, Clinical Development
        • COVID-19, Translational Strategy
      • Oncology Pipeline
      • Cofinanced Projects
      • Collaboration with Scientific Associations
      • Publications
      • Mechanisms of Action
      • Medical meeting presentations
    • Shareholders and Investors
      • Financial Information
        • Annual Reports
        • Interim financial information
        • Financial Statements (Zeltia)
        • Average Period of Payment to Suppliers
      • Notifications sent to CNMV
      • Share Information
        • Share Performance
        • Shares Outstanding
        • Dividends
        • Significant Shareholding & Company Owned-Stock
        • Analysts
      • Debt Obligations
      • Presentations
      • General Shareholders Meetings
      • Corporate Governance
        • Corporate Bylaws
        • General Shareholders’ Meeting Regulations
        • Shareholder Agreements
        • Board of Directors
        • Board of Directors Regulation
        • Annual Report on Corporate Governance
        • Annual Director Remuneration Report
        • Board Committees
        • Internal Regulation Governing Conduct
      • Contact
      • Merger PharmaMar-Zeltia
      • Política de Comunicación con Accionistas
    • Newsroom
      • Press Releases
      • Events calendar
      • Multimedia
        • Videos
        • Infographics
      • Medical meeting presentations
    • Careers
      • Benefits
      • Send us your CV

    Category Archives: CNMV_EN

    You are here:
    1. Home
    2. Category "CNMV_EN"
    3. (Page 29)

    Se adjunta nota de prensa sobre la participación de Pharma Mar en el Simposio Anual de la EORTC-NCI-AACR celebrado en Berlín.

    CNMV_ENBy admin23 November, 2010

    Janssen Pharmaceuticals ha informado a Pharma Mar sobre la situación del procedimiento regulatorio en Australia.

    CNMV_ENBy admin12 November, 2010

    La sociedad remite nota de prensa sobre los resultados correspondientes al tercer trimestre 2010

    CNMV_ENBy admin28 October, 2010

    Centocor Ortho Biotech Products ha informado a Pharma Mar de la aprobación de Yondelis® para cáncer de ovario recurrente platino-sensible en Brasil, India y Argentina.

    CNMV_ENBy admin1 October, 2010

    El Appraisal Committee del NICE no recomienda que el NHS británico reembolse el tratamiento de Yondelis para cáncer de ovario. El NICE aún debe emitir su recomendación final (“Final Guidance”)

    CNMV_ENBy admin17 September, 2010

    La FDA ha concedido la condición de “Fast Track” a Tideglusib (ZentylorTM), fármaco de Noscira actualmente en Fase II de desarrollo clínico para el tratamiento de la Parálisis Supranuclear Progresiva

    CNMV_ENBy admin9 September, 2010

    Centocor Ortho Biotech Products ha informado a Pharma Mar de la aprobación de Yondelis® para cáncer de ovario recurrente platino-sensible en Rusia.

    CNMV_ENBy admin8 September, 2010

    Se adjunta nota de prensa en la que se anuncia que Sylentis, filial de Zeltia, ha completado la Fase Ia del primer ensayo clínico de su producto en gotas de solución oftálmica SYL040012 para el tratamiento de la presión intraocular elevada y glaucoma

    CNMV_ENBy admin6 July, 2010

    Se informa que todas las propuestas de acuerdos presentadas por el Consejo a la Junta General han sido aprobadas.

    CNMV_ENBy admin29 June, 2010

    Se remite copia de la presentación a accionistas que será realizada en la Junta General de Zeltia por el Presidente y por la Directora Financiera de dicha Sociedad.

    CNMV_ENBy admin29 June, 2010

    299

    1
    234567891011121314151617181920212223242526
    …2728293031
     Dream-Theme — truly premium WordPress themes
    Sobre PharmaMar
    Go to Top
    We use our own and third-party cookies in order to collect statistical information and to ensure the best experience on our site. If you want to accept them, click I agree.I agreeI do not acceptPrivacy policy
    You can revoke your consent any time using the Revoke consent button.Revoke consent